Condition: Sickle Cell Disease · Vaso-Occlusive Pain Episode in Sickle Cell Disease · Ketamine Infusion · Sponsor: Mohsen Saidinejad
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
This description comes directly from the study's public registry record.
Cynthia Luo, MD · 310-222-2345 · cluo2@dhs.lacounty.gov
Mohsen Saidinejad, MD · moh@emedharbor.edu
Always discuss trial participation with your own doctor first.
| Harbor UCLA Medical Center | Torrance, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07369024